<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11924105</article-id><article-id pub-id-type="pmcid-ver">PMC11924105.1</article-id><article-id pub-id-type="pmcaid">11924105</article-id><article-id pub-id-type="pmcaiid">11924105</article-id><article-id pub-id-type="manuscript-id">NIHMS2058442</article-id><article-id pub-id-type="pmid">39549364</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2024.112463</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2058442</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2058442</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>AN UPDATED VIEW ON THE INFLUENCE OF INITIAL OPIOID PRESCRIPTION CHARACTERISTICS ON LONG-TERM OPIOID USE AMONG OPIOID NA&#207;VE PATIENTS</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="AM">Allen M</given-names></name><degrees>PharmD</degrees><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shah</surname><given-names initials="A">Anuj</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names initials="BC">Bradley C</given-names></name><degrees>Pharm.D, PhD</degrees><xref rid="A1" ref-type="aff">a</xref></contrib></contrib-group><aff id="A1"><label>a</label>Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, 4301 W. Markham, slot 522, Little Rock, AR 72205, USA</aff><aff id="A2"><label>b</label>AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878, USA.</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Contributors</p><p id="P2">Allen M Smith (First Author): Formal analysis, Visualization, Writing &#8211; Original Draft, Writing &#8211; Review &amp; Editing</p><p id="P3">Anuj Shah (Second Author): Visualization, Methodology, Writing &#8211; Review &amp; Editing</p><p id="P4">Bradley C Martin (Senior Author): Data Curation, Conceptualization, Methodology, Writing &#8211; Review &amp; Editing, Visualization, Supervision</p></fn><corresp id="CR1">Author to which correspondence should be addressed: Bradley C Martin, Pharm.D., Ph.D. Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, 4301 W. Markham, slot 522, Little Rock, AR 72205, <email>bmartin@uams.edu</email></corresp><fn fn-type="COI-statement" id="FN5"><p id="P53">Conflict of Interest</p><p id="P54">Dr. Martin receives royalties from TrestleTree, LLC for the commercialization of an opioid risk prediction tool that used separate data sources and methods and is unrelated to this investigation.</p><p id="P55">Dr. Shah is an employee of AstraZeneca and has stocks of Gilead Sciences and Roche, none of which are related to this study</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>24</day><month>10</month><year>2024</year></pub-date><volume>265</volume><issue-id pub-id-type="pmc-issue-id">484764</issue-id><fpage>112463</fpage><lpage>112463</lpage><pub-history><event event-type="nihms-submitted"><date><day>13</day><month>03</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-21 10:25:13.500"><day>21</day><month>03</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2058442.pdf"/><abstract id="ABS1"><sec id="S1"><title>OBJECTIVES:</title><p id="P5">This retrospective cohort study provides an updated view on the association between the likelihood of long-term opioid use (LTOU) and characteristics of the initial opioid prescription (dose, opioid type) and initial opioid prescription episode (days&#8217; supplied) among opioid-na&#239;ve patients utilizing IQVIA PharMetrics<sup>&#174;</sup>Plus for Academics database representative of commercially insured patients in the US.</p></sec><sec id="S2"><title>METHODS:</title><p id="P6">Kaplan-Meier estimates were used to determine opioid continuation likelihood at 365 days stratified by the characteristics of the initial opioid prescription and initial opioid prescription episode. Cox-proportional hazard models were estimated to determine the strength of association between initial opioid prescription characteristics and opioid continuation.</p></sec><sec id="S3"><title>RESULTS:</title><p id="P7">A total of 578,403 cancer-free, SUD-free, opioid-na&#239;ve subjects aged &#8805;14 years that filled &#8805;1 opioid prescriptions between April 13, 2016 and April 18, 2020 were identified and categorized based on time to opioid discontinuation. After accounting for censoring, 5.05% of persons continued opioid use for &#8805;365 days. Compared to a 1&#8211;2 days&#8217; supply (DS), the likelihood of opioid discontinuation was consistently lower with higher DS [HRs (CIs): 3&#8211;4 days&#8217; supply = 0.66 (0.65&#8211;0.66); 5&#8211;7 DS = 0.41 (0.41&#8211;0.41); 8&#8211;10 DS = 0.33 (0.33&#8211;0.34); 11&#8211;14 DS = 0.30 (0.29&#8211;0.31); 15&#8211;21 DS = 0.26 (0.26&#8211;0.27); &#8805;22 DS = 0.17 (0.17&#8211;0.18)]. These associations between increased DS and decreased likelihood of discontinuing opioid remained consistent across different pain etiologies.</p></sec><sec id="S4"><title>CONCLUSIONS:</title><p id="P8">In this era of more conservative opioid prescribing, increases in DS remains the strongest factor associated with a higher likelihood of LTOU.</p></sec></abstract><kwd-group><kwd>long-term opioid use</kwd><kwd>prescribed opioids</kwd><kwd>pain etiology</kwd><kwd>days&#8217; supply</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>